The AGTR1 gene¹¹ AGTR1 gene
encodes the angiotensin II type 1 receptor, a critical component of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure, fluid balance, and cardiovascular function. The A1166C variant (rs5186) is the most well-studied AGTR1 SNP, located in the 3′ untranslated region . While it doesn't change the protein sequence directly, it may affect mRNA stability and transcription, or be in linkage disequilibrium with another polymorphism of regulatory significance .

The Mechanism

This variant sits in the 3' UTR²² 3' UTR
the untranslated region after the protein-coding sequence where regulatory elements control gene expression.

The AGTR1 A1166C polymorphism may influence the stability of mRNA expression and might be involved in cellular signaling mediated by the angiotensin II receptor . Some studies have found that the C allele is associated with reduced AGTR1 mRNA levels — 0.8-fold lower in heterozygotes and 0.27-fold lower in homozygotes compared to AA carriers , though findings are inconsistent across studies.

The AT1 receptor mediates the effects of angiotensin II, causing vasoconstriction, sodium retention, increased blood pressure, and activation of inflammatory pathways. The receptor is the target of ARBs³³ ARBs
angiotensin receptor blockers, a class of blood pressure medications including losartan, valsartan, candesartan, and irbesartan.

The Evidence

The relationship between rs5186 and hypertension has been extensively studied but remains controversial.

A systematic review and meta-analysis of AGTR1 polymorphisms and hypertension found that the literature is too heterogeneous to draw meaningful conclusions , with insufficient evidence that polymorphisms in the AGTR1 gene are risk factors for hypertension . However, specific populations and conditions show clearer associations.

For cardiovascular outcomes⁴⁴ For cardiovascular outcomes, a meta-analysis of 53 studies with 20,435 CHD cases and 23,674 controls found only a weak association between A1166C and coronary heart disease, likely due to publication bias and heterogeneity . In contrast, the rs5186 polymorphism significantly increases the risk of restenosis after percutaneous coronary intervention (PCI) in Asian populations .

For metabolic conditions⁵⁵ For metabolic conditions, the gain-of-function rs5186 A1166C variant has been linked to hypertension, cardiovascular disease, and metabolic syndrome .

The variant affects liver disease, insulin resistance, and endothelial dysfunction in NAFLD, at least in part by modulating adipokine, chemokine, and pro-inflammatory cell activation in response to fat ingestion .

For kidney health⁶⁶ For kidney health, the C allele shows an odds ratio of 1.84 for diabetic nephropathy in Iranian patients , and shows a likelihood ratio of 1.89-2.01 for GFR depletion in type 2 diabetes patients .

For brain health⁷⁷ For brain health,

C1166 variant carriers show significantly larger subcortical hyperintensity volume compared to AA genotype carriers in healthy older adults , suggesting the C1166 variant may serve as a biomarker of risk for suboptimal brain integrity prior to changes in cognition .

Practical Implications

The primary clinical relevance of rs5186 is in predicting response to ARB medications.

Individuals with the AC genotype show significant reduction in systolic blood pressure after candesartan medication in Chinese populations .

The percentage of systolic BP reduction with candesartan-based treatment was greater in patients with AC genotypes compared to AA homozygotes .

However, carrying the 1166C allele is associated with greater compensatory increase in renin activity and more modest effect on aldosterone after candesartan treatment , suggesting long-term RAAS activation that may affect clinical outcomes.

The variant also has implications beyond blood pressure. Given its associations with metabolic syndrome, NAFLD, diabetic nephropathy, and cerebrovascular changes, C allele carriers may benefit from closer monitoring of metabolic health, kidney function, and cardiovascular risk factors — particularly if they have diabetes or metabolic syndrome.

Interactions

AGTR1 rs5186 functions as part of the renin-angiotensin-aldosterone system pathway. It may interact with other RAAS-related SNPs including ACE I/D (rs4340), which affects angiotensin-converting enzyme activity and modifies response to ACE inhibitors, and AGT M235T (rs699), which influences angiotensinogen levels and blood pressure. Studies suggest that individuals with multiple RAAS pathway variants show cumulative effects on hypertension risk and treatment response. The variant's effects may also be modified by CYP2C9 polymorphisms, particularly for ARBs metabolized by this enzyme like losartan and irbesartan.

Your immune cells depend on a precisely organized cell membrane to function. The outer leaflet of every immune cell membrane is kept nearly free of phosphatidylserine — a lipid that, when exposed on the surface, signals "eat me" to phagocytes and dampens T-cell activation. A family of proteins called P4-ATPases (phospholipid flippases) does this housekeeping work, pumping phosphatidylserine¹¹ phosphatidylserine
A negatively charged phospholipid that is normally sequestered on the inner face of the plasma membrane; when it flips to the outer leaflet, it triggers apoptosis recognition and dampens immune signaling from the outer leaflet back inside. ATP8B4 is one of these flippases, expressed at especially high levels in bone marrow and immune-relevant tissues. The rs55687265 variant — a C allele on the plus strand creating the amino acid change Phe436Leu in the protein's transmembrane transport domain — appears to compromise this pumping activity, with measurable consequences for autoimmune disease risk.

The Mechanism

ATP8B4 belongs to the P4-type ATPase subfamily (also called type IV ATPases or phospholipid flippases). These enzymes use ATP hydrolysis to flip specific phospholipids from the outer to the inner leaflet of cellular membranes — maintaining the lipid asymmetry that is fundamental to healthy cell signaling. Disruption of this asymmetry in immune cells alters how those cells interpret and transmit inflammatory signals. In dendritic cells and macrophages, improper phosphatidylserine distribution on the plasma membrane affects toll-like receptor clustering²² toll-like receptor clustering
TLRs are pattern-recognition receptors that initiate innate immune responses; their signaling efficiency depends partly on local membrane lipid composition and downstream NF-kB activation dynamics.

The F436L substitution replaces a phenylalanine with a leucine in the transmembrane transport domain of the enzyme. Phenylalanine at this position is conserved across P4-ATPase family members and is predicted to participate in the phospholipid-binding pocket's geometry. Changing it to leucine — a smaller, less aromatic residue — is predicted to reduce substrate affinity or transport rate. Differential expression³³ Differential expression
SSc patients showed significantly altered ATP8B4 transcript levels compared to controls (P = 0.0005), consistent with a functional role in disease of ATP8B4 was observed between SSc patients and controls at the mRNA level, supporting biological involvement beyond just the genetic association.

The Evidence

The primary evidence comes from a whole-exome sequencing study⁴⁴ whole-exome sequencing study
WES sequences the protein-coding regions of the genome; rare variant burden analyses aggregate low-frequency variants by gene to detect associations too rare to find with single-SNP tests by Gao et al. (2016, Arthritis & Rheumatology, PMID 26473621) that performed gene-level burden analysis in European-American systemic sclerosis patients with and without pulmonary arterial hypertension. The rs55687265 variant emerged as the single strongest association signal within ATP8B4 — discovery cohort P = 9.35 × 10⁻¹⁰, OR 6.11. Replication in 415 SSc cases and 2,848 controls yielded OR 1.86 (P = 0.012). Meta-analysis across both cohorts: OR 2.5 (P = 1.92 × 10⁻⁷). Gene-level burden for all ATP8B4 rare variants reached P = 2.77 × 10⁻⁷.

A subsequent analysis by López-Isac et al.⁵⁵ López-Isac et al.
A multi-center European consortium follow-up study examining the F436L variant in an independent Spanish, Italian, German, and Dutch SSc cohort (2017, PMID 28141915) specifically assessed rs55687265 in a larger European-American SSc population. ATP8B4 gene-level burden was also detected in African American SSc patients⁶⁶ African American SSc patients
Whole-exome sequencing in 148 African American SSc cases and 2,397 controls; ATP8B4 among enriched genes (Gourh et al., 2018, PMID 29732714), extending the biological signal beyond European ancestry.

In parallel, a landmark Nature Genetics exome study⁷⁷ Nature Genetics exome study
16,036 Alzheimer's disease cases and 16,522 controls; gene-level burden test using SKAT-O across all rare damaging variants per gene (Holstege et al., 2022, PMID 36411364) of 32,558 individuals identified rare damaging variants across ATP8B4 as a significant Alzheimer's disease risk gene — placing it alongside TREM2, SORL1, and ABCA1 as genes involved in lipid membrane homeostasis in brain tissue, particularly in microglia.

The evidence across systemic sclerosis and Alzheimer's disease points to a shared mechanism: defective phospholipid flipping in immune cells (peripheral in SSc, central microglia in Alzheimer's) disrupts membrane lipid asymmetry, alters phagocytic and inflammatory signaling, and ultimately increases susceptibility to chronic dysregulated inflammation.

Practical Actions

The C allele at rs55687265 is rare globally (~1.4% overall, ~1.5% in Europeans, essentially absent in East Asians). Most carriers will be heterozygous GC. The elevated OR from the discovery cohort (OR 6.11) may reflect ascertainment bias from a highly selected SSc-with-PAH enriched sample; the replication OR of 1.86 and meta-analytic OR of 2.5 are better estimates of effect size in the general population. This is a meaningful but not deterministic risk factor — the C allele raises susceptibility, it does not guarantee disease.

Given the phospholipid transport mechanism, interventions that support membrane lipid composition and reduce chronic immune activation are most relevant. Omega-3 fatty acids (EPA/DHA) directly incorporate into immune cell membranes, modifying the pool of lipid substrates that flippases act on. Antioxidants that protect phospholipids from oxidation — particularly astaxanthin and vitamin E — reduce the load of oxidatively damaged phospholipids that accumulate when flipping is impaired.

Interactions

ATP8B4 belongs to the same P4-ATPase family as ATP8B1 (expressed in hepatocytes and bile ducts) and ATP8B2. The biological overlap with ABCA1 is particularly notable — ABCA1 is another lipid transporter independently identified as an Alzheimer's disease risk gene in the same Holstege et al. study, and both genes participate in cholesterol and phospholipid homeostasis in macrophages and microglia. Carriers of risk variants in both ATP8B4 and ABCA1 may face compounding lipid transport defects in immune cells, though no published compound analysis exists yet for this pair.

Systemic sclerosis as a disease involves dysregulated fibrotic and vascular responses alongside immune activation. Established SSc risk loci include rs2476601 (PTPN22), rs3087243 (CTLA4), and rs6920220 (TNFAIP3), which operate through T-cell and B-cell regulation rather than membrane lipid transport. ATP8B4 represents a distinct biological pathway into SSc susceptibility.

LD Redundancy Flag

IMPORTANT NOTE FOR REVIEW: rs6165 (Ala307Thr) and rs6166 (Asn680Ser) are in near-complete linkage disequilibrium. Published studies report D'=0.997 and r²=0.82–0.99 across populations¹¹ Published studies report D'=0.997 and r²=0.82–0.99 across populations
Vietnamese cohort study, 2025: OR=490 for sharing the same genotype between the two SNPs. The two variants form a fixed haplotype in most populations: Ala307-Ser680 (CC at rs6165, GG at rs6166) is the reduced-sensitivity haplotype; Thr307-Asn680 (TT at rs6165, AA at rs6166) is the high-sensitivity haplotype. Because r² exceeds 0.80, rs6165 may be informationally redundant with rs6166 for most clinical purposes. The key question for platform inclusion is whether the Ala307Thr amino acid change provides independent mechanistic information beyond Asn680Ser. Current evidence suggests it does — the extracellular glycosylation mechanism is distinct — but genotypically these SNPs rarely differ in real-world data. This entry is maintained for completeness and for users whose genome file happens to include one but not the other.

The Extracellular Hinge Variant That Shapes How FSH Binds Its Receptor

The FSH receptor (FSHR) is a glycoprotein with a large extracellular domain that captures circulating FSH, and an intracellular signaling domain that converts FSH binding into cAMP production. While rs6166 (Asn680Ser) sits in the intracellular domain and alters the kinetics of cAMP signaling, rs6165 affects an entirely different part of the receptor. The Ala307Thr substitution is located in the [hinge region²² The Ala307Thr substitution is located in the [hinge region
The region connecting the leucine-rich repeat domain to the transmembrane domain] of the extracellular domain.

The Mechanism

The Ala307Thr change (coding strand G→A, representing threonine substituting for alanine at position 307) introduces a threonine residue where alanine previously sat. Critically, this substitution removes a potential [O-linked glycosylation site | A site where sugar chains can be added to the protein, altering its stability, folding, and binding properties]. Glycosylation at this position is thought to influence FSH binding affinity directly — the Ala307 variant (the ancestral form, encoded by the coding-strand G allele, which appears as C in genome files due to the minus-strand orientation of the FSHR gene) lacks this glycosylation site, while Thr307 carries it.

The consequence is that the Ala307 haplotype is associated with altered FSH affinity in the extracellular domain³³ Ala307 haplotype is associated with altered FSH affinity in the extracellular domain
Complementing the intracellular kinetic changes caused by the linked rs6166 Ser680 variant. In practice, because these two variants are almost always inherited together, it is difficult to distinguish their independent contributions clinically. What is consistent is that the Ala307-Ser680 haplotype (CC at rs6165 plus GG at rs6166 in plus-strand notation) is associated with reduced FSH receptor sensitivity overall — an effect attributable to both the extracellular binding change (Ala307Thr) and the intracellular signaling change (Asn680Ser) acting in concert.

The Evidence

The most direct evidence for rs6165 specifically comes from a 2025 study of 79 Vietnamese women with diminished ovarian reserve⁴⁴ 2025 study of 79 Vietnamese women with diminished ovarian reserve
Hoang et al. Applied Clinical Genetics, 2025. Women with the GG genotype at rs6165 (coding notation: Ala/Ala) retrieved significantly fewer total oocytes (4.63 vs 5.73, p=0.04), showed lower follicular output rate (FORT) and follicular oocyte index (FOI), and were 490 times more likely to also carry the GG genotype at rs6166 (p<0.0001) — confirming the near-complete haplotype structure.

A 2024 systematic review and meta-analysis⁵⁵ 2024 systematic review and meta-analysis
Association of FSHR gene polymorphisms with poor ovarian response in patients undergoing IVF, Gene 2024 covering 6 studies and 444 POR cases versus 875 controls found that the T allele of rs6165 (Thr307, which carries the glycosylation site) is associated with higher POR risk in Caucasian populations: T vs C allelic OR=1.64 (95% CI 1.25–2.16); homozygous TT vs CC OR=2.76 (95% CI 1.43–5.32). Note: this result — where the Thr allele (T on plus strand) associates with poor response — appears to contrast with some haplotype data, and may reflect population-specific allele frequency differences or heterogeneity across studies. The biological interpretation remains that the Ala307-Ser680 haplotype overall associates with reduced FSH sensitivity, even where individual allele OR directions vary across studies.

A 2024 multicenter prospective study across Europe and Asia⁶⁶ 2024 multicenter prospective study across Europe and Asia
The Additive Effect of Combinations of FSH Receptor Gene Variants in Ovarian Response to Stimulation, Reproductive Sciences 2024 examining diplotypes found that the rs6165/rs6166 AG/AG combination was associated with more hypo-response (33.1% vs 24.0%, adjOR 1.77, 95% CI 1.08–2.90) compared to other diplotypes, while GG/AA showed less hypo-response (19.1% vs 31%, adjOR 0.48, 95% CI 0.24–0.96). This additive diplotype approach confirms that combination genotyping provides better prediction than either SNP alone.

For PCOS susceptibility, a 2017 case-control study of 377 PCOS women and 388 controls⁷⁷ 2017 case-control study of 377 PCOS women and 388 controls
FSH receptor gene p.Thr307Ala and p.Asn680Ser polymorphisms are associated with the risk of PCOS, Journal of Assisted Reproduction and Genetics 2017 found the Ala/Ala genotype had an OR of 2.23 for PCOS (95% CI 1.38–3.68), and confirmed near-complete LD between rs6165 and rs6166 (r²≈99%).

Practical Implications

Because rs6165 and rs6166 are almost always co-inherited, the clinical guidance for rs6165 largely mirrors that for rs6166. Women with the CC genotype at rs6165 (Ala/Ala, the reduced-sensitivity haplotype) should expect a pattern similar to GG carriers at rs6166: potentially reduced oocyte yield at standard FSH doses, compensatory higher basal FSH levels, and the need for dose adjustment in IVF. The critical practical point is that elevated day-3 FSH in these women may reflect receptor sensitivity rather than diminished ovarian reserve⁸⁸ elevated day-3 FSH in these women may reflect receptor sensitivity rather than diminished ovarian reserve
AMH testing, which is not regulated through the FSH receptor, gives a receptor-independent reserve estimate.

Women with the TT genotype (Thr/Thr, carrying the glycosylation site) tend to be more FSH-sensitive, similar to AA carriers at rs6166. An early Indian cohort study found that Ala/Ala women required the lowest FSH doses and had the highest OHSS rate (85%)⁹⁹ Indian cohort study found that Ala/Ala women required the lowest FSH doses and had the highest OHSS rate (85%)
Achrekar et al. Fertility and Sterility 2009, though this study was small and the 85% OHSS figure reflects a highly selected clinical sample.

The Ala307Thr variant adds mechanistic nuance to FSHR pharmacogenetics beyond Asn680Ser: the extracellular glycosylation change likely contributes to FSH binding affinity independently, meaning that haplotype-level information (combining both variants) may refine prediction beyond either SNP alone.

Interactions

rs6166 (FSHR Asn680Ser): The dominant interaction for rs6165. These two variants are in near-complete LD (r²=0.82–0.99, D'=0.997) and form a two-variant haplotype: Ala307-Ser680 (CC + GG, reduced sensitivity) and Thr307-Asn680 (TT + AA, higher sensitivity). Because they are almost never discordant in real genotype data, the clinical guidance is essentially identical. A compound action for the concordant high-risk haplotype (CC at rs6165 + GG at rs6166) is warranted if both SNPs are available in a user's genome file, but would activate for <1% of users who are discordant at the two positions. The rs6166 entry in the hormones-sleep category provides comprehensive IVF dosing guidance for this haplotype.

rs1394205 (FSHR promoter variant): The FSHR promoter polymorphism at rs1394205 (G-29A) operates upstream of both coding variants and influences total receptor expression level independently of receptor sensitivity. A 2024 additive diplotype study¹⁰¹⁰ 2024 additive diplotype study
Reproductive Sciences 2024 found that the rs6165/rs1394205 combination reduced oocyte yield (EMD -1.99, 95% CI -3.57 to -0.42) and FOI (EMD -12.07) in certain diplotype combinations, confirming independent additive effects.

Compound action proposal for rs6165 CC + rs6166 GG (Ala307-Ser680/Ala307-Ser680 homozygous haplotype): Women who are CC at rs6165 AND GG at rs6166 carry the homozygous reduced-sensitivity FSHR haplotype with changes at both the extracellular binding domain (Ala307) and the intracellular signaling domain (Ser680). The combined recommendation would be: request AMH rather than FSH for ovarian reserve assessment; use urinary FSH (uFSH/Menopur) at higher starting doses in IVF; track basal FSH trends as a personal benchmark rather than vs population reference ranges; and discuss the double-variant status with a reproductive endocrinologist before any ovarian stimulation. Evidence level: strong.

Von Willebrand factor (VWF) does two jobs in haemostasis: it captures platelets at sites of vascular injury, and it acts as a molecular chaperone that binds and shields coagulation factor VIII¹¹ factor VIII
the clotting protein deficient in haemophilia A; VWF keeps it from being degraded in the bloodstream before it is needed from premature proteolytic clearance. The rs61748497 variant — encoding the p.Cys1060Arg substitution in the D3 domain — specifically cripples the second job. VWF quantity is normal, platelet plug formation is intact, but FVIII levels fall because the carrier protein can no longer hold its cargo. The result is a condition classified as von Willebrand disease type 2N²² von Willebrand disease type 2N
named for Normandy, France, where the subtype was first described — a bleeding disorder that mimics haemophilia A but arises from a VWF gene defect rather than an FVIII gene defect.

The Mechanism

The VWF gene sits on the minus strand of chromosome 12p13.31. The rs61748497 variant is described as c.3178T>C on the coding strand (NM_000552.5), which corresponds to the plus-strand genomic change NC_000012.12:g.6025624A>G. The substitution converts codon 1060 from TGT (cysteine) to CGT (arginine) — p.Cys1060Arg. Cysteine residues frequently participate in disulphide bonds that maintain tertiary protein structure; the C1060 residue is located in the C8_3 subdomain of the D3 domain, a region critical for the three-dimensional architecture of the VWF-FVIII interaction interface.

Przeradzka et al. (2018)³³ Przeradzka et al. (2018)
Przeradzka MA et al. The D' domain of VWF requires the presence of the D3 domain for optimal factor VIII binding. Biochem J. 2018 used chemical footprinting mass spectrometry to demonstrate that C1060R induces conformational changes in the D3 domain that are quantitatively proportional to the reduction in FVIII binding affinity. The mutation does not simply remove a single contact point — it disrupts the overall fold of the D3 domain in a way that reduces the capacity of the neighbouring D' domain (the canonical FVIII binding site) to engage factor VIII effectively. The result is a FVIII binding capacity that ranges from severely reduced to completely absent depending on whether the patient carries one or two copies of the mutant allele.

The Evidence

The definitive characterization of C1060R comes from Hilbert et al. (2003)⁴⁴ Hilbert et al. (2003)
Hilbert L et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of VWF, are responsible for decreased FVIII-binding capacity. Br J Haematol. 2003;120(4):627-32, who identified the mutation in seven unrelated French families with type 2N VWD and confirmed its functional impact through site-directed mutagenesis and transient expression in COS-7 cells. C1060R was found in heterozygous, homozygous, and compound heterozygous states, with phenotypic severity tracking the number of mutant alleles. Its occurrence outside the originally described FVIII-binding tryptic fragment (D' domain, residues 764–1035) established that D3 domain integrity is independently required for FVIII binding.

The index description of a clinically important compound heterozygous case appears in Mazurier et al. (2002)⁵⁵ Mazurier et al. (2002)
Mazurier C et al. Factor VIII deficiency not induced by FVIII gene mutation in a female first cousin of two brothers with haemophilia A. Br J Haematol. 2002;119(2):390-2: a 20-year-old woman with reduced FVIII activity was initially thought to be an obligate carrier of the family's haemophilia A mutation. She was instead found to carry compound heterozygosity for Y357X (a VWF null allele, rs61754002) and C1060R. Her VWF antigen levels were very low due to the null allele, her VWF:FVIII binding was undetectable, and her FVIII activity was severely reduced — a phenotype indistinguishable from haemophilia A on conventional testing. This case illustrates the diagnostic trap: any female presenting with isolated FVIII deficiency should have VWF molecular testing before haemophilia A carrier status is assumed.

The 2021 ASH/ISTH/NHF/WFH diagnostic guidelines⁶⁶ 2021 ASH/ISTH/NHF/WFH diagnostic guidelines
James PD et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD. Blood Adv. 2021;5(1):280-300 specifically include a diagnostic algorithm for type 2N: low FVIII with normal or borderline VWF antigen and ristocetin cofactor activity is the laboratory signature. Confirmation requires a VWF:FVIII binding assay — a test that directly measures VWF's capacity to bind factor VIII at physiological conditions. Genetic testing (sequencing of VWF exons encoding the D' and D3 domains) is recommended alongside phenotypic assays because heterozygous carriers can present with borderline laboratory values, and accurate diagnosis is essential for correct treatment.

Practical Actions

The critical clinical point is that desmopressin (DDAVP) does not correct the type 2N defect. Desmopressin releases stored VWF from endothelial cells, temporarily raising VWF antigen and — secondarily — FVIII levels. But the released VWF still carries the C1060R mutation and cannot bind FVIII normally: within hours, FVIII levels fall back as unprotected factor VIII is cleared from circulation. For haemostasis in type 2N patients, only VWF/FVIII concentrate (which delivers functional FVIII directly alongside VWF) reliably restores haemostatic competence. The 2021 management guidelines⁷⁷ 2021 management guidelines
Connell NT et al. ASH ISTH NHF WFH 2021 guidelines on the management of VWD. Blood Adv. 2021;5(1):301-325 recommend VWF/FVIII concentrate as the treatment of choice for type 2N, targeting VWF activity and FVIII activity ≥0.50 IU/mL peri-operatively.

Heterozygous carriers may or may not have measurable clinical phenotypes, depending on FVIII levels. Some carriers have FVIII in the low-normal range (40–60 IU/dL) and are entirely asymptomatic; others fall below normal thresholds and have mild bleeding symptoms, particularly around surgery or childbirth.

Interactions

C1060R is most clinically significant in compound heterozygous combination with a VWF null allele — where one allele produces no VWF protein and the other produces VWF that cannot bind FVIII. The index case (Mazurier 2002) carried C1060R together with Y357X (rs61754002), a nonsense allele that produces no VWF at all. In that combination, VWF antigen is reduced (driven by the null allele), VWF:FVIII binding is abolished (driven by C1060R), and FVIII activity is critically low — a full phenotypic haemophilia A presentation in a VWF gene carrier. Any VWF null allele (type 3 disease allele) on the second chromosome would produce a similar compound effect.

Blood group O independently lowers VWF antigen by 15–25%, which may push a heterozygous C1060R carrier's effective FVIII levels further below the normal range and worsen clinical bleeding phenotype without affecting the molecular defect.

Sex hormone-binding globulin is the liver's principal carrier for testosterone and estradiol. Only a tiny fraction of circulating testosterone — roughly 1–3% — is truly free and biologically active; SHBG tightly binds the rest, holding it in reserve. Rs6259 changes one amino acid deep in SHBG's C-terminal domain, and the consequence is biochemically elegant: the substitution creates a new site where sugar chains can attach to the protein. That extra glycosylation extends SHBG's survival in the bloodstream, pushing circulating SHBG concentrations higher — and shifting the balance between bound and free sex hormones.

The Mechanism

The variant converts aspartate to asparagine at position 356 of the SHBG precursor protein (position 327 in the older mature-protein numbering, giving rise to the historically common "Asp327Asn" or "D327N" designation in older literature). Asparagine at this position creates an [N-linked glycosylation consensus sequence | The sequence motif Asn-X-Ser/Thr, where X is any amino acid except proline, is recognized by the oligosaccharyltransferase complex in the endoplasmic reticulum as a site for N-linked sugar chain attachment] that the wild-type aspartate does not support.

A key nuance: [biochemical studies of SHBG glycosylation | Bocchinfuso et al. Endocrinology 1992, PMID 1425432; Hammond & Bocchinfuso J Steroid Biochem Mol Biol 1995, PMID 7626508] show that N-linked carbohydrate chains do NOT alter SHBG's steroid-binding affinity for testosterone or dihydrotestosterone. The extra glycosylation does not make SHBG bind more or less tightly to testosterone at the steroid-binding pocket (located in the N-terminal domain). Instead, the primary effect is on SHBG's metabolic fate: the additional sugar chain is thought to [increase protein half-life | by masking protease cleavage sites and modulating hepatic clearance receptors; the C-terminal domain containing this glycosylation site is also involved in SHBG's membrane receptor interactions] in the bloodstream, resulting in higher steady-state SHBG concentrations. Higher total SHBG means more testosterone is bound — reducing free androgen availability even though each SHBG molecule binds testosterone with unchanged affinity.

There is also a haplotype-level interaction: the [Thompson 2008 haplotype analysis | Thompson et al. Cancer Epidemiol Biomarkers Prev 2008, PMID 19064566] of 11 SHBG SNPs found that the rs6259 A allele (D356N) specifically neutralizes the SHBG-lowering effect of the rs858518/ rs727428 haplotype. When D356N is present on the same chromosomal background as the otherwise SHBG-lowering haplotype, the expected drop in SHBG does not occur — making rs6259 a key modifier of other SHBG variants' effects.

The Evidence

The clearest quantitative evidence comes from a 2009 study of men across three age groups¹¹ 2009 study of men across three age groups
Vanbillemont et al. Clin Endocrinol (Oxf) 2009, PMID 18681858, which found that A allele carriers in the middle-aged cohort had 14.2% higher SHBG (P<0.001) and 7.3% higher total testosterone (P=0.01) compared to GG homozygotes, with no significant change in free testosterone — consistent with the body maintaining free testosterone homeostasis through LH feedback while total SHBG rises.

A 2025 sibling study of 999 Dutch men²² 2025 sibling study of 999 Dutch men
Walravens et al. J Clin Endocrinol Metab 2025, PMID 38652149 confirmed that rs6259 A allele carriers showed higher SHBG and total testosterone with no clear effect on measured free testosterone. In the Dunning 2004 study of postmenopausal women³³ Dunning 2004 study of postmenopausal women
JNCI 2004, PMID 15199113, D356N was significantly associated with circulating SHBG levels (P=0.005) and the estradiol-to-SHBG ratio (P=0.01), explaining 0.6% of SHBG variance.

In the context of PCOS and metabolic syndrome, higher SHBG from the A allele appears protective. A Chinese Han male study (n=384)⁴⁴ Chinese Han male study (n=384)
Pang et al. Aging Clin Exp Res 2014, PMID 24671943 found A allele carriers had significantly lower metabolic syndrome risk (OR 0.56, 95% CI 0.33–0.96) alongside higher SHBG. A meta-analysis of 4,733 participants⁵⁵ meta-analysis of 4,733 participants
Li et al. Reprod Biomed Online 2021, PMID 33168491 found rs6259 was not significantly associated with PCOS risk overall — consistent with the larger Liao & Cao 2020 meta-analysis (1,660 PCOS cases, 1,312 controls, PMID 32589470) that also found no significant PCOS association. The mechanistic expectation (higher SHBG → lower free androgen index → protective against PCOS) is biologically plausible, but the genetic signal is not robust across all populations.

For breast cancer, a meta-analysis of 10,454 cases and 13,111 controls⁶⁶ meta-analysis of 10,454 cases and 13,111 controls
Zhou et al. Mol Biol Rep 2012, PMID 22711300 found no significant overall association with the Asp356Asn variant, but a protective effect emerged specifically in postmenopausal Asian women (dominant model OR 0.83, 95% CI 0.70–0.97). A Shanghai population-based study (1,106 cases, 1,180 controls) confirmed this pattern⁷⁷ confirmed this pattern
Cui et al. Cancer Epidemiol Biomarkers Prev 2005, PMID 15894658, finding OR 0.73 (95% CI 0.53–0.99) in postmenopausal women, with the strongest protection in lean women (OR 0.46) — consistent with the A allele raising SHBG, thereby sequestering more estradiol in the lower-estrogen postmenopausal environment.

An unexpected finding comes from prostate cancer: a Japanese study of 70 men on androgen deprivation therapy⁸⁸ Japanese study of 70 men on androgen deprivation therapy
Shiota et al. Clin Genitourin Cancer 2019, PMID 31036465 found that A allele carriers had dramatically worse outcomes, with HR 2.20 for progression (P=0.027) and HR 3.21 for mortality (P=0.012), despite comparable testosterone suppression across genotypes. The mechanism remains under investigation — one hypothesis is that higher SHBG levels in A allele carriers paradoxically maintain a reservoir of bioavailable androgen through SHBG membrane receptor-mediated signaling, which may fuel castration-resistant prostate cancer progression through non-classical androgen pathways.

For bone health, a study of postmenopausal women⁹⁹ study of postmenopausal women
Napoli et al. Bone 2009, PMID 19679209 found that A allele carriers had significantly lower bone mineral density at the total femur (P=0.004) and intertrochanter (P=0.002), without detectable differences in free estradiol — suggesting the skeletal effect may be mediated through SHBG's membrane receptor signaling or other estrogen-independent mechanisms.

Practical Implications

For most people, rs6259 GG genotype is the common variant (approximately 79% globally). A allele carriers — particularly AA homozygotes, who are rare (~1% of the population) — have measurably higher SHBG and a distinct hormone profile. The practical implications are most relevant for: (1) interpreting sex hormone panels (higher SHBG inflates total testosterone while free testosterone may be maintained); (2) prostate cancer treatment planning, where genotype may influence ADT response; and (3) breast cancer risk stratification in postmenopausal Asian women.

Interactions

rs727428 and rs858518 (SHBG regulatory variants): The Thompson 2008 haplotype analysis showed that rs6259 D356N neutralizes the SHBG-lowering haplotype formed by rs858518 and rs727428. A person carrying the A allele at rs6259 alongside the T allele at rs727428 or the A allele at rs858518 will partially or fully offset the expected SHBG reduction from those regulatory variants. This is relevant for anyone carrying risk genotypes at multiple SHBG loci — the net SHBG effect is the sum of all contributing variants, with rs6259 A acting as a counterweight to the rs727428/rs858518 lowering effect.

rs1799941 (SHBG promoter G-68A): This promoter variant in the hormones-sleep category also regulates SHBG levels through expression changes. Carriers of both rs1799941 A allele (higher SHBG) and rs6259 A allele (higher SHBG) would have additive SHBG-raising effects. For PCOS risk assessment and prostate cancer ADT planning, total SHBG genotype burden across all four SHBG variants (rs727428, rs858518, rs1799941, rs6259) provides the most informative picture.

Proposed interaction for supervisor review: Men with GA or AA genotype at rs6259 who are considering or undergoing androgen deprivation therapy for prostate cancer should have rs6259 genotype documented alongside baseline SHBG levels, as the Shiota 2019 data suggest this may be an independent prognostic factor for ADT response regardless of testosterone suppression depth.

When a gout attack strikes, the pain is driven not just by uric acid crystals lodging in a joint — it's driven by the inflammatory cascade those crystals ignite. PRKG2 encodes cGMP-dependent protein kinase II (cGKII)¹¹ cGMP-dependent protein kinase II (cGKII)
a serine/threonine kinase activated by cyclic GMP, expressed in intestinal epithelium, kidney, cartilage, and immune cells, a signaling enzyme that turns out to sit at a key amplification point in this cascade. The intronic variant rs6837293 was identified as a possible gout-susceptibility locus in a Taiwanese genome-wide analysis — but replication has been elusive, leaving its clinical significance unsettled.

The Mechanism

cGKII phosphorylates the CFTR chloride channel in intestinal epithelium, regulates renin secretion in the kidney, and supports endochondral bone growth — but its most relevant role for gout is in immune cells. A 2015 study by Zhou et al.²² A 2015 study by Zhou et al.
Zhou et al. Cyclic GMP-dependent protein kinase II is necessary for macrophage M1 polarization and phagocytosis via toll-like receptor 2. J Mol Med, 2015 demonstrated that cGKII expression is high in M1-polarized macrophages (the pro-inflammatory phenotype) but low in M2 (anti-inflammatory) macrophages. When scientists silenced cGKII, M1 activation was significantly reduced. Critically, when macrophages were exposed to monosodium urate (MSU) crystals — the trigger of gout attacks — cGKII and toll-like receptor 2 (TLR2) expression both increased, amplifying M1 polarization and phagocytic activity. Knocking down cGKII blunted the MSU-induced inflammatory response.

This positions PRKG2 as an inflammation amplifier in gout: variants that alter cGKII expression or activity could modulate how intensely the innate immune system responds to urate crystals. The intronic location of rs6837293 suggests a regulatory rather than coding mechanism — potentially affecting PRKG2 expression levels in relevant tissues.

The Evidence

Initial discovery — Taiwanese population: Chang et al. 2009³³ Chang et al. 2009
Chang SJ et al. The cyclic GMP-dependent protein kinase II gene associates with gout disease: identified by genome-wide analysis and case-control study. Ann Rheum Dis, 2009 identified PRKG2 through a genome-wide analysis in 8 gout patients and 10 unaffected relatives, then validated in a case-control study of 74 male gout patients and 74 age-matched healthy controls from a Taiwanese population. Both rs6837293 and rs7688672 showed significant association with gout under a recessive model (rs6837293 OR = 2.72, 95% CI 1.13–6.54; rs7688672 OR = 2.89, 95% CI 1.19–7.02), and the association remained after adjusting for serum uric acid levels — suggesting that PRKG2 may influence gout risk through the inflammatory response to crystals rather than through urate concentration alone.

Replication failure — Japanese population: Sakiyama et al. 2014⁴⁴ Sakiyama et al. 2014
Sakiyama M et al. Common variants of cGKII/PRKG2 are not associated with gout susceptibility. J Rheumatol, 2014 attempted replication in a substantially larger Japanese cohort: 741 male gout patients and 1,302 controls. All four PRKG2 variants — including rs6837293 — showed no association with gout in any genetic model (allele frequency, dominant, or recessive). The authors concluded that cGKII is not involved in gout susceptibility.

Mixed results — Chinese cohort: Guo et al. 2015⁵⁵ Guo et al. 2015
Guo M et al. Polymorphism of rs7688672 and rs10033237 in cGKII/PRKG2 and gout susceptibility of Han population in northern China. Gene, 2015 tested different PRKG2 variants in 405 gout cases and 429 controls (Han Chinese), finding rs10033237 associated with gout but rs7688672 not — further highlighting the inconsistency of PRKG2 findings across populations and variant sets.

Taken together, the evidence for rs6837293 is emerging at best. The original study was small (74 cases), and the larger replication failed. The biological mechanism — cGKII amplifying urate crystal inflammation — is plausible and supported by in vitro data, but the specific role of this intronic variant remains unestablished.

Practical Actions

For TT homozygotes, the empirical gout-susceptibility signal (even if fragile) points toward the inflammatory arm of gout rather than the urate-production arm. This means standard urate-lowering dietary measures are still relevant but may need to be paired with attention to foods and supplements that modulate innate immune activation.

Limiting dietary purines (organ meats, shellfish, red meat, alcohol — especially beer and spirits) reduces urate substrate and therefore crystal formation risk regardless of PRKG2 genotype. If cGKII does amplify the inflammatory response to existing crystals, maintaining serum urate well below the crystallisation threshold of 6.8 mg/dL becomes more important for TT carriers than for CC carriers.

Serum uric acid monitoring is the most actionable next step — a fasting uric acid test can stratify actual hyperuricemia risk, which is the prerequisite for crystal formation regardless of downstream inflammatory gene variants.

Interactions

With SLC2A9 rs3733591 and ABCG2 rs2231142: SLC2A9 and ABCG2 are the strongest determinants of serum urate concentration (explaining ~5% of variance each). PRKG2, if genuinely involved in gout susceptibility, would represent a downstream effector operating after crystal formation — meaning the combination of high-urate genotypes (SLC2A9 C/C, ABCG2 T/T) plus the proposed PRKG2 rs6837293 TT genotype might confer both elevated crystal burden and an amplified inflammatory response, though no study has examined this combination directly.

With rs7688672 (PRKG2): The original Taiwanese study found both rs6837293 and rs7688672 associated with gout under a recessive model. These two intronic PRKG2 variants may be in linkage disequilibrium and tag the same underlying functional signal. Carriers of TT at both loci may represent the subgroup with the most consistent PRKG2-related risk signal.

The rs693 variant, known historically as the XbaI polymorphism, sits in exon 26 of the APOB gene¹¹ APOB gene
apolipoprotein B, the structural protein of LDL particles. Despite being a "silent" or synonymous mutation—the DNA change from C to T doesn't alter the amino acid (both code for threonine)—this variant has surprisingly robust effects on blood lipid levels and cardiovascular risk. It's a reminder that not all functional variants change protein sequence²² It's a reminder that not all functional variants change protein sequence
some affect mRNA stability, splicing efficiency, or are in linkage disequilibrium with truly causal variants.

The Mechanism

The rs693 SNP changes position 7673 in the APOB gene from cytosine (C) to thymine (T), creating a restriction site for the XbaI enzyme—hence its historical name. This transition occurs at codon 2488, changing ACC to ACT, but both encode threonine. Despite the synonymous nature, the A allele is consistently associated with elevated apolipoprotein B levels³³ Despite the synonymous nature, the A allele is consistently associated with elevated apolipoprotein B levels
the key structural protein in LDL, VLDL, and other atherogenic particles.

The mechanism likely involves effects on mRNA stability or translation efficiency rather than direct protein structure changes. ApoB is the main protein component of LDL particles⁴⁴ LDL particles
each LDL particle contains exactly one ApoB-100 molecule, making ApoB count a direct measure of atherogenic particle number. More ApoB means more LDL particles capable of infiltrating arterial walls and initiating atherosclerosis.

The Evidence

The evidence for rs693's cardiovascular impact is substantial. A 2017 meta-analysis of 61 studies including 50,018 subjects⁵⁵ 2017 meta-analysis of 61 studies including 50,018 subjects
showed A allele carriers had significantly higher ApoB levels (SMD 0.26), LDL-C (SMD 0.22), total cholesterol (SMD 0.24), and triglycerides (SMD 0.12). They also had slightly lower HDL-C (SMD -0.06).

In a Brazilian elderly cohort of 644 individuals⁶⁶ Brazilian elderly cohort of 644 individuals
AA homozygotes had mean LDL and total cholesterol levels about 10 mg/dL higher than CC or GA genotypes, with Cohen's d effect sizes of 0.35 for LDL. While 10 mg/dL may seem modest, population studies show that a 27 mg/dL increase in total cholesterol translates to 25-30% higher coronary disease incidence.

A meta-analysis specific to Han Chinese populations⁷⁷ meta-analysis specific to Han Chinese populations
analyzed 1,195 CHD patients and 1,178 controls, confirming the XbaI A allele confers significant CHD risk. The 2008 Malmö Diet and Cancer Study⁸⁸ 2008 Malmö Diet and Cancer Study
created a 9-SNP genotype score including rs693 that independently predicted 10-year cardiovascular events (MI, stroke, CHD death).

The A allele frequency varies dramatically by ancestry: 49-50% in Europeans, 38% in Africans and Latinos, 45% in South Asians, but only 2-10% in East Asians. This makes the variant particularly relevant for European-ancestry individuals, where roughly half the population carries at least one copy.

Practical Implications

If you're a T carrier (CT or AA genotype), your baseline lipid profile is likely shifted toward higher atherogenic particle counts. This doesn't guarantee cardiovascular disease— many factors contribute to risk—but it does mean your LDL particle number may be higher than LDL-C alone would suggest. ApoB directly measures particle number⁹⁹ ApoB directly measures particle number
and is increasingly recognized as superior to LDL-C for risk assessment when discordant.

Dietary response may differ by genotype. Saturated fat intake tends to raise LDL-C more in those genetically predisposed to higher ApoB production. Some evidence suggests T carriers benefit more from dietary modifications targeting particle number reduction: prioritizing monounsaturated fats, increasing soluble fiber, and limiting refined carbohydrates that drive VLDL and small dense LDL production.

Statin response can vary by APOB genotype, though rs693 itself has shown mixed results in pharmacogenetic studies. More important is ensuring treatment targets account for ApoB or non-HDL-C, not just LDL-C, if you're a T carrier—your particle number may be higher than cholesterol-based calculations suggest.

Interactions

The APOB rs693 variant interacts with other lipid-related SNPs to influence cardiovascular risk. The Kathiresan 9-SNP score¹⁰¹⁰ Kathiresan 9-SNP score
includes rs693 along with variants in APOE, LDLR, PCSK9, CETP, and other lipid genes, showing additive effects on LDL elevation and CVD risk. Those with multiple unfavorable alleles across these genes show progressively higher LDL and ApoB levels.

The related rs17240441 variant (a 9-bp insertion/deletion in APOB exon 1) also affects ApoB and lipid levels, with combined effects possible when both variants are present. Additionally, variants in MTHFR (like rs1801133) can interact with lipid metabolism through homocysteine pathways, potentially compounding cardiovascular risk in those with elevated ApoB.

Dietary gene-nutrient interactions are relevant: the effect of rs693 on lipid levels may be modified by saturated fat intake, omega-3 consumption, and overall dietary pattern. Some studies suggest Mediterranean-style diets may attenuate the lipid-raising effects of the A allele more effectively than high-saturated-fat Western diets.

Every adaptive immune response requires a second signal beyond antigen recognition. The OX40–OX40L axis¹¹ OX40–OX40L axis
OX40 (CD134) is a co-stimulatory receptor on activated T cells; its ligand OX40L (CD252) is expressed on antigen-presenting cells and provides the survival and proliferation signal that determines whether a T cell response is sustained or terminated is one of the most important of those second signals — controlling whether activated T cells survive, expand into effector cells, and help B cells mature into antibody-secreting plasma cells. TNFSF4, the gene encoding OX40 ligand (OX40L), sits on chromosome 1q25 and contains a regulatory upstream region that has been consistently implicated in systemic autoimmunity. rs7514229 is an intronic variant within TNFSF4 that tags this regulatory haplotype and has been linked to altered OX40L expression, autoimmune thyroid disease, and viral immune control.

The Mechanism

rs7514229 maps to an intronic position within TNFSF4 on chromosome 1 (GRCh38 chr1:173,185,165). TNFSF4 itself is transcribed from the minus strand, but dbSNP reports alleles on the plus strand — the reference allele is G, the alternate allele is T. As an intronic variant, rs7514229 does not change the OX40L amino acid sequence; instead, it serves as a tag for a broader upstream regulatory haplotype²² a broader upstream regulatory haplotype
Cunninghame Graham et al. Nature Genetics 2008 (PMID 18059267) identified four SNPs showing significant overtransmission in SLE families and demonstrated that susceptibility alleles were associated with a 6.7-fold increase in TNFSF4 transcript expression (P=0.008) in the TNFSF4 promoter region.

The functional consequence is altered OX40L surface expression. Higher OX40L on antigen-presenting cells strengthens OX40 signaling on T cells, promoting T cell survival beyond the normal timeframe, amplifying Th2-skewed responses, and providing excessive help to B cells in germinal centers — driving sustained antibody production, including autoantibodies. Bioinformatic analysis of the intronic rs7514229-T allele suggests it may also disrupt miRNA binding sites³³ miRNA binding sites
A regulatory mechanism by which microRNA molecules bind to complementary sequences in mRNA, typically in untranslated regions, to suppress gene expression, potentially further modulating TNFSF4 transcript stability or translation.

The Evidence

The foundational association between TNFSF4 and autoimmunity was established in a landmark 2008 Nature Genetics paper⁴⁴ landmark 2008 Nature Genetics paper
Cunninghame Graham et al. — two independent European SLE cohorts (UK WTCCC + US NIH), 36 SNPs across TNFSF4, four showing significant overtransmission; risk haplotype carriers showed 6.7-fold elevated TNFSF4 RNA expression in cells with susceptibility alleles that genotyped rs7514229 among 36 TNFSF4 variants and linked the upstream haplotype to SLE through elevated OX40L expression. This was subsequently replicated⁵⁵ replicated
Delgado-Vega et al. Genes & Immunity 2009 (PMID 19092840) — 1,312 cases, 1,801 controls; four European and Argentine cohorts; pooled OR=1.38–1.39 for the tagging haplotype across multiple European and Latin American populations.

Directly at rs7514229, a 2016 Chinese case-control study⁶⁶ 2016 Chinese case-control study
Song et al. Int J Mol Sci 2016 (PMID 27556446) — 1,048 AITD patients and 909 healthy controls, Han Chinese; four tagging SNPs in the TNFSF4 region found that the GG genotype at rs7514229 (homozygous reference, no T allele) was significantly associated with early-onset autoimmune thyroid disease (AITD) in patients aged ≤18 years. This population-specific finding, where G is the major allele in East Asians (~89%), points to a complex regulatory relationship in which the T/G haplotype context — rather than a simple additive dose — determines TNFSF4 expression thresholds relevant to thyroid autoimmunity during adolescent immune development.

A 2021 Chinese HCV study⁷⁷ 2021 Chinese HCV study
Fu et al. Frontiers in Genetics 2021 (PMID 33841497) — 3,690 participants including 2,309 uninfected controls, 597 spontaneous clearers, and 784 persistent HCV infection patients; false discovery rate corrected found rs7514229-T associated with increased HCV persistence risk. Individuals carrying multiple risk alleles (rs7514229-T plus rs3181366-T) showed a dose-dependent increase in infection susceptibility (P_trend<0.001), with bioinformatic evidence that T disrupts a miRNA binding site affecting TNFSF4 transcript regulation.

Practical Implications

OX40L/TNFSF4 operates at the interface of T cell survival and B cell help — two processes central to the autoimmune cycle. Carriers of rs7514229-T may have altered OX40L expression that shifts this balance toward sustained immune activation. The actionable response focuses on early recognition of autoimmune thyroid disease, one of the most common OX40L-linked conditions, and awareness of HCV risk in relevant contexts.

Autoimmune thyroid disease presents in two main forms: Graves' disease⁸⁸ Graves' disease
Autoimmune hyperthyroidism where TSH receptor autoantibodies stimulate thyroid hormone overproduction; characterized by weight loss, heat intolerance, palpitations, and sometimes exophthalmos (bulging eyes) and Hashimoto's thyroiditis⁹⁹ Hashimoto's thyroiditis
Autoimmune hypothyroidism where lymphocytic infiltration destroys thyroid tissue; characterized by fatigue, cold intolerance, weight gain, and goiter. Both are diagnosable with standard thyroid function tests (TSH, free T4, free T3) and thyroid autoantibodies (anti-TPO, anti-thyroglobulin, TSH receptor antibodies).

Interactions

TNFSF4 does not operate in isolation from the broader autoimmune susceptibility landscape. A gene-gene interaction study in Chinese SLE¹⁰¹⁰ gene-gene interaction study in Chinese SLE
Wang et al. 2011 (PMID 21905002) — multiplicative interaction model in 806 cases and 806 controls found a significant interaction between BLK rs2736340 and TNFSF4 in SLE susceptibility (P=6.57×10⁻⁴). BLK encodes a B-cell tyrosine kinase critical for self-tolerance; reduced BLK expression (from the rs2736340 risk allele) combined with elevated OX40L co-stimulation from the TNFSF4 risk haplotype creates a dual defect — impaired B cell tolerance plus amplified T cell help for autoreactive B cells. The nearby TNFSF4 variants rs2205960 and rs1234317 (from the SLE-associated haplotype) and rs3850641 (associated with Hashimoto's hypothyroidism) represent functionally overlapping signals within the same regulatory region that may compound with rs7514229 on the same haplotype.

Interleukin-13¹¹ Interleukin-13
IL-13 is a Th2 cytokine produced by mast cells, basophils, ILC2 innate lymphoid cells, and activated CD4+ helper T cells; it drives IgE class-switching in B cells, mucus hypersecretion in airway epithelium, airway smooth-muscle hyperresponsiveness, and suppression of epidermal barrier proteins including filaggrin is one of the most consequential mediators of allergic inflammation. At chromosome 5q31.1, a cluster of interrelated variants spans the IL13 gene and nearby regulatory elements, forming a haplotype block that has emerged as one of the strongest and most consistently replicated genetic loci in allergy genetics.

rs1295686 is an intronic variant within IL13 located at chr5:132,660,151 (GRCh38). It does not change the IL-13 protein sequence — its significance lies in the haplotype it marks. The minor T allele co-segregates tightly with rs20541 (the missense variant that produces the hyperactive Q130 form of IL-13) and rs1295685 (a 3'-UTR regulatory variant linked to enhanced mRNA stability). Together, these three variants — plus rs848 and rs847 — define the IL13 risk haplotype block at 5q31.1 that has been linked to atopic dermatitis, asthma, allergic rhinitis, elevated serum IgE, and IgE-mediated food allergy across dozens of independent studies.

The Mechanism

As an intronic variant, rs1295686 does not alter IL-13 protein function directly. Luciferase reporter and chromosome conformation capture experiments²² Luciferase reporter and chromosome conformation capture experiments
Li et al. Am J Respir Cell Mol Biol 2022 — identified functional SNPs at the locus as rs1295685, rs848, and rs847, which form a haplotype that interacts with the promoter of TH2LCRR, a long non-coding RNA with elevated expression in asthma patients show that the causal functional effect at this locus operates through a haplotype interacting with TH2LCRR — a long non-coding RNA elevated in asthmatic airways. rs1295686 lies in strong linkage disequilibrium with this functional haplotype and with rs20541, which changes amino acid 130 of the IL-13 protein from arginine (R, lower receptor affinity) to glutamine (Q, higher receptor engagement and enhanced signaling through IL-13Rα1).

When the T allele at rs1295686 is present, the carrier almost invariably also carries the rs20541-A (Q130) and rs1295685-A risk alleles. The combined effect of these co-inherited variants is higher constitutive IL-13 pathway activity: elevated circulating IL-13 protein with enhanced receptor engagement drives persistent IgE production in B cells, mucus hypersecretion and airway hyperresponsiveness in the lung, and epidermal barrier disruption through STAT6-mediated suppression of filaggrin and loricrin in the skin.

The Evidence

The 5q31.1 IL13/RAD50 locus is among the most robust signals in atopy genetics. A 2023 European and multi-ancestry GWAS meta-analysis³³ 2023 European and multi-ancestry GWAS meta-analysis
Budu-Aggrey et al. Nature Communications; ~21,000 cases and ~95,000 controls in European discovery, 2.9 million in 23andMe replication placed the IL13/SLC22A5 5q31 locus at P<10⁻³⁶ for atopic dermatitis — one of the most significant signals in human atopy genetics. rs1295686 lies within this haplotype block.

For food allergy specifically, a challenge-confirmed pediatric cohort study⁴⁴ challenge-confirmed pediatric cohort study
Ashley et al. Clin Exp Allergy 2017; discovery n=722 (367 food-allergic cases, 199 sensitized-tolerant, 156 controls) and replication n=533 (203 cases, 330 controls) found the T allele at rs1295686 associated with IgE-mediated food allergy at OR=1.75 (p=0.003) in discovery and OR=1.37 (p=0.03) in replication; the meta-analysis yielded OR=1.50 (p=0.0006). This study confirmed complete LD between rs1295686 and rs20541, establishing that the intronic tag and the coding functional variant travel together on the same risk haplotype.

For total serum IgE, a genome-wide association study in the Framingham Heart Study⁵⁵ genome-wide association study in the Framingham Heart Study
Granada et al. J Allergy Clin Immunol 2012; 6,819 Framingham participants plus 5 independent replication cohorts identified rs1295686 as one of three loci reaching genome-wide significance (P=3.55×10⁻⁸) for elevated total plasma IgE — alongside FCER1A (the high-affinity IgE receptor) and STAT6 (the primary IL-13 downstream transcription factor).

For asthma, analyses in Chinese pediatric and adult cohorts⁶⁶ Chinese pediatric and adult cohorts
Tang et al. Pediatr Allergy Immunol 2016; 903 asthmatic children, 1,205 controls; 479 adult asthmatics, 746 controls found rs1295686 associated with adult asthma (OR=1.64) and early-onset asthma (OR=1.92), confirming IL13 and GSDMB as replicated asthma genes. A study in Saudi Arabian adults⁷⁷ Saudi Arabian adults
Halwani et al. J Asthma 2018 found the T allele at rs1295686 conferred OR=1.69 (p=0.008) for symptomatic asthma, extending the association beyond European ancestry.

The African-ancestry T allele frequency is markedly higher (~66%) than in Europeans (~20%), reflecting population-specific LD patterns. This does not translate directly into higher atopic disease rates, as gene-environment interactions differ, but it does mean the risk allele is substantially more common in individuals of African descent — a factor relevant to genetic counseling in diverse populations.

Practical Implications

Carrying one or two copies of the T allele at rs1295686 indicates membership in the IL-13 high-activity haplotype. The practical consequence is a higher baseline Th2 bias: more IL-13 activity, higher IgE production, and increased susceptibility to the full atopic triad (eczema, allergic rhinitis, asthma) and IgE-mediated food allergy. Measuring serum total IgE quantifies how biologically active this IL-13 pathway is in the individual.

For those with active atopic disease inadequately controlled by topical or standard therapies, the IL-13/IL-4 pathway is the genetically-indicated target. IL-13-specific biologics (tralokinumab) and IL-4Rα inhibitors (dupilumab) directly neutralize the cytokine pathway this haplotype overactivates. Skin barrier protection with ceramide emollients addresses the downstream consequence — filaggrin suppression — of high IL-13 signaling.

Interactions

rs1295686 lies in near-complete linkage disequilibrium with rs20541⁸⁸ rs20541
IL-13 R130Q missense variant; Q130 form engages IL-13Rα1 with higher affinity, driving stronger JAK1/STAT6 signaling in B cells, airway epithelium, and skin keratinocytes and rs1295685⁹⁹ rs1295685
IL-13 3'-UTR variant affecting mRNA stability, on the same risk haplotype block. Carriers of the T allele at rs1295686 are thus almost invariably also carrying the rs20541-A and rs1295685-A risk alleles.

The downstream receptor partner for IL-13 signaling is IL-4Rα (encoded by IL4R, variant rs1801275). Carriers of both the IL-13 haplotype risk allele (rs1295686-T) and the IL4R risk allele may face compounding Th2 dysregulation — elevated IL-13 ligand activity meeting altered receptor signal transduction — with pharmacogenomic relevance to dupilumab response, which acts directly on the shared IL-4/IL-13 receptor subunit.

The upstream regulatory hub rs2040704 (in the RAD50/TH2LCRR region) coordinates expression of the IL-4/IL-5/IL-13 cytokine gene cluster. Combined risk allele status at both rs1295686 and rs2040704 may represent compounding Th2 amplification from different regulatory levels.

Inside every pancreatic beta cell, a molecular tug-of-war determines your fasting blood glucose set point. Glucokinase¹¹ Glucokinase
An enzyme that phosphorylates glucose to glucose-6-phosphate (G6P), initiating glycolysis and triggering insulin release acts as an accelerator, driving glucose into the glycolytic pathway. G6PC2 acts as the brake — it hydrolyzes G6P back into free glucose, creating a futile cycle that raises the glucose concentration required to trigger insulin secretion. The balance between these two enzymes defines the glucose-sensing threshold²² glucose-sensing threshold
The minimum blood glucose concentration that stimulates meaningful insulin release from beta cells — your personal fasting glucose set point.

rs1402837 sits 646 bp upstream of the G6PC2 transcription start site, in a region of open chromatin in human pancreatic islets. It is in very high linkage disequilibrium³³ linkage disequilibrium
LD r²=0.97, meaning the two variants are inherited together 97% of the time and tag the same underlying signal with the lead GWAS variant rs34177044. When the T allele disrupts regulatory element activity at this position, less G6PC2 is expressed in beta cells — the brake eases, glycolytic flux increases at lower glucose concentrations, and the fasting glucose set point shifts downward.

The Mechanism

G6PC2 is expressed almost exclusively in pancreatic islets, where it counteracts glucokinase by converting G6P back to glucose. This substrate futile cycle⁴⁴ futile cycle
A metabolic loop that dissipates energy without net product synthesis; here it makes the beta cell less sensitive to rising glucose raises the glucose level at which insulin secretion is triggered. Research from 2025 also showed that G6PC2 operates in alpha cells, where it defines the glucose concentration at which glucagon secretion is suppressed — linking the locus to both hormonal arms of glucose regulation. ⁵⁵ Bahl et al. 2025 Science Translational Medicine — G6PC2 controls glucagon set point in alpha cells; allele-specific expression confirmed at linked variants

The rs1402837 T allele falls in an open chromatin region detected by H3K4me3 ChIP-seq in human islets, consistent with a cis-regulatory role. It is one of several upstream variants (alongside intronic and promoter variants such as rs560887, rs573225, and rs2232316) that collectively modulate G6PC2 transcript abundance and, consequently, the fasting glucose set point.

The Evidence

The association between the G6PC2 locus and fasting glucose is one of the most strongly replicated signals in human metabolic genetics. rs1402837 specifically was identified in a genome-wide scan of HbA1c⁶⁶ genome-wide scan of HbA1c
Paré et al. 2008 — novel association of HK1 and G6PC2 loci with glycated haemoglobin in 14,618 non-diabetic women; rs1402837 p=6.8×10⁻¹⁰, explaining 0.2% of HbA1c variance in 14,618 apparently healthy Caucasian women. The variant is in very high LD with the fasting glucose lead signal rs34177044, which was replicated in 5,786 non-diabetic Chinese individuals at p=6.9×10⁻¹² (β=0.145 mmol/L per glucose-raising allele) ⁷⁷ Spracklen et al. 2018 PLoS Genetics — functional analysis of glycemic trait loci in the China Health and Nutrition Survey.

The broader G6PC2 locus has been studied in meta-analyses covering up to 187,968 non-diabetic participants, confirming that variants at this locus collectively explain approximately 1–2% of fasting glucose variance — a substantial fraction for common genetic variants. Importantly, the glucose-raising effect is seen without increased type 2 diabetes risk in most populations, consistent with G6PC2's role in setting the fasting setpoint rather than impairing overall glucose tolerance. ⁸⁸ Baerenwald et al. 2013 Diabetologia — multiple functional G6PC2 polymorphisms contribute additively to fasting plasma glucose elevation

The gene is also expressed in alpha cells, where it regulates glucagon suppression threshold. Recent functional studies showed that G6pc2 deletion in alpha cells improves glucose-mediated glucagon suppression, pointing to a bihormonal mechanism and a potential therapeutic target for pharmacological inhibition.

Practical Actions

The T allele at rs1402837 lowers the fasting glucose set point through reduced G6PC2 expression. Carriers benefit from an inherently lower fasting glucose baseline that requires no intervention. For those with the common CC genotype — where both copies of the C reference allele maintain full G6PC2 expression — the glucose set point sits higher. While this is not pathological, it represents a quantifiable contribution to lifetime glycemic load. The most actionable lever for CC carriers is limiting dietary inputs that directly challenge the already-higher fasting glucose threshold: refined carbohydrates and high-glycemic foods raise postprandial glucose spikes that interact with the elevated set point. Spreading carbohydrate intake across smaller, more frequent meals — rather than large boluses — reduces peak beta-cell demand. Regular aerobic activity independently lowers the fasting glucose set point through AMPK-mediated pathways that do not involve G6PC2.

Interactions

The G6PC2 fasting glucose signal is additive with variants in glucokinase (GCK, rs1799884) and the glucokinase regulatory protein gene (GCKR, rs1260326), which operate on the same beta-cell glucose-sensing pathway from the opposite direction. Individuals carrying glucose-raising alleles at both G6PC2 and GCK show compounded effects on fasting glucose and insulin secretion capacity. The combined risk allele score across G6PC2, GCK, GCKR, and MTNR1B variants is associated with meaningful fasting glucose elevation and increased type 2 diabetes risk. ⁹⁹ Li et al. 2009 Diabetes — additive effects of GCK and G6PC2 variants on insulin secretion and fasting glucose (BetaGene + METSIM cohorts)